Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Botox tested as a remedy for facial flushing

NCT ID NCT02216838

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This study investigates whether injections of botulinum toxin A (Botox) can treat persistent facial flushing. In a split-face design, each participant receives Botox on one side of the face and a saline placebo on the other, allowing direct comparison. The trial enrolls 16 adults aged 18 to 65 with ongoing facial flushing and measures changes using a spectrophotometer. As a pilot study, it aims to see if this approach is worth studying further.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
botulinum toxin A (Botox)
What this could lead to
If effective, Botox could offer a new option for people bothered by persistent facial redness.
What could go wrong
This is a very small pilot study with only 16 people, so results may not apply broadly. Botox injections carry risks like bruising or temporary muscle weakness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

16 people

The number who actually took part.

Start date

Aug 2014

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients 18-65 years of age with persistent facial flushing 2. Willing and have the ability to understand and provide informed consent for participation in the study and are able to communicate with the study staff. Exclusion Criteria: 1. Unable to understand the protocol or give informed consent 2. Younger than 18 or older than 65 years of age 3. Females who are pregnant or lactating 4. Known hypersensitivity to BTX-A 5. Subjects using medications that interfere with neuromuscular functions (such as aminoglycoside antibiotics) 6. Subjects who have a history of congestive heart failure, carcinoid syndrome, mastocystosis, or renal cell carcinoma 7. Botulinum toxin injections in the past 6 months 8. Ablative laser procedure in the past 6 months 9. Radiofrequency device treatment in the past 6 months 10. Ultrasound device treatment in the past 6 months 11. Medium to deep chemical peel in the past 6 months 12. Temporary soft tissue augmentation material in the area to be treated in the past year 13. Semi-permanent soft tissue augmentation material in the area to be treated in the past 2 years 14. Permanent soft tissue augmentation material in the area to be treated 15. Is planning to receive within the next 6 months, any cosmetic procedure (such as any chemical peels, botulinum toxin injections, ablative or non-ablative laser procedures, filler injections, radiofrequency procedures, dermabrasion, ultrasound and face lifting procedures) in the forehead or glabellar region. 16. Is planning to use tretinoin or retinoic acid in the next 6 months 17. Has an active infection in the forehead or glabellar region (excluding mild acne) 18. Is allergic to cow's milk protein 19. Is allergic to albumin 20. Is currently using anticoagulation therapy 21. Has a history of bleeding disorders

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Facial flushing are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Blushing

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Northwestern University Feinberg School of Medicine, Department of Dermatology

    Chicago, Illinois, 60611, United States